Results 171 to 180 of about 280,511 (259)
Resolution pharmacology is an emerging strategy to tackle inflammatory pathologies. Bioinspired meroterpenoids induce a lipid mediator class switch toward inflammation resolution in vitro and in vivo by targeting key nodes in lipid mediator biosynthesis and neutral lipid dynamics.
Lorenz Waltl +20 more
wiley +1 more source
B cells can be activated independently of antigen recognition via mechanical stimulation through nanoporous substrates. Exposure to such substrates induced B cell microvilli extension into the pores, intracellular Ca2+ signaling, phosphorylation of signaling proteins, and CD69 expression.
Nozie D. Aghaizu +4 more
wiley +1 more source
An HNSCC syngeneic mouse model for tumor immunology research and preclinical evaluation. [PDF]
Fu Y, Tian G, Li J, Zhang Z, Xu K.
europepmc +1 more source
BCG HSP70 Reprograms Macrophages via Central Trained Immunity to Suppress Prostate Cancer
BCG‐derived HSP70 (Dnak) safely induces central trained immunity via epigenetic, metabolic, and O‐GlcNAcylation reprogramming of bone marrow progenitors, driving tumor‐associated macrophages toward an M1‐like phenotype to suppress prostate cancer. ABSTRACT Trained immunity offers a promising yet clinically challenging strategy for cancer immunotherapy,
Peng Liu +12 more
wiley +1 more source
Lymphatic vessels, miRNAs, and CAR T cells in tumor immunology. [PDF]
Jiang X.
europepmc +1 more source
In glioblastoma, M2‐polarized macrophages secrete IL‐6, which activates STAT3 signaling in tumor cells to upregulate CTSB. Tumor‐derived CTSB binds the C‐terminus of macrophage S100A10, reinforcing M2 polarization and further IL‐6 secretion, thereby establishing a feedforward IL‐6/STAT3/CTSB/S100A10 loop. This cascade drives tumor growth, invasion, and
Hao Zhang +11 more
wiley +1 more source
Redirecting Monocyte Differentiation With Engineered Extracellular Vesicles for Glioma Immunotherapy
A dual‐targeting engineered extracellular vesicles (M1‐CS‐EVs) platform is developed to redirect monocytes differentiation into anti‐tumor macrophages for glioma immunotherapy. This nanoplatform combines CAR‐mediated tumor recognition with localized CD47 blockade, leading to synergistic immune activation and potent suppression of tumor progression in ...
Yuanwei Pan +9 more
wiley +1 more source
The Gela/decitabine/La2(CO3)3 colloidal (GDLC) hydrogel developed here could reverse the epigenetic silencing of the GSDME gene by the synergistic interaction between DAC and La3+, while concurrently activating caspase‐3, thus facilitating pyroptosis induction under the tumor microenvironment.
Yang Hong +6 more
wiley +1 more source
High glucose is linked to reduced succinate dehydrogenase activity in CD14+ monocytes, accompanied by succinate accumulation and extracellular release. Extracellular succinate exacerbates mitochondrial ROS production and mtDNA release in CD4+ T cells. Cytosolic mtDNA then activates Z‐DNA binding protein 1 (ZBP1) and engages ZBP1‐associated inflammatory
Shuai Zhao +11 more
wiley +1 more source
TSTScope is an interpretable AI framework that integrates single‐cell transcriptomes with TCR information through curated gene‐program constraints. By linking receptor context to functional T cell states, it reveals response‐associated tumor‐specific T cell programs in lung cancer immunotherapy cohorts and defines an MPR score associated with ...
Shiwei Cao +8 more
wiley +1 more source

